ASCO 2017 | Avelumab in locally advanced or metastatic solid tumors

Dr James Gulley, MD, PhD from the Centre for Cancer Research, Bethesda, MD discusses the response rates of second-line avelumab in patients with advanced non-small cell lung cancer (NSCLC) at the American Society of Oncology (ASCO) 2017 Annual Meeting held in Chicago, IL. The JAVELIN solid tumor trial (NCT01772004) investigated the safety and tolerability of avelumab as the dose was escalated, in subjects with metastatic or locally advanced solid tumors. Some interesting results were produced from this trial, resulting in a more effective treatment that we currently have, however this is only a hypothesis. Further trials are required to provide more evidence for this hypothesis.